S. 1414Introduced
Expedited Access to Biosimilars Act
Plain-English overview
What this bill does
Modifies FDA biosimilar approval requirements by generally removing mandatory clinical efficacy studies and changing review procedures for biosimilar applications
Key points
- Amend biosimilar study requirements
- Modify FDA review assignment
- Allow FDA to require efficacy studies
Current status
Where it stands
Status
Introduced
Latest action
2026-07-27 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.